Scientific article
Case report

Fulminant multifocal relapse in a fingolimod-treated multiple sclerosis patient

Published inMultiple Sclerosis and Related Disorders, vol. 34, p. 63-65
Publication date2019

Fingolimod is the first approved oral disease-modifying treatment for relapsing-remitting multiple sclerosis. Fingolimod targets lymphocytes, exerting a modulator effect on cell-surface sphingosine-1-phosphate receptors and thus blocking lymphocytes egression from secondary lymphoid organs. Recent reports describe fingolimod cessation being followed by severe or pseudo-tumoral relapse, but it usually does not happen on continuous long-term treatment.

Citation (ISO format)
BREVILLE, Gauthier et al. Fulminant multifocal relapse in a fingolimod-treated multiple sclerosis patient. In: Multiple Sclerosis and Related Disorders, 2019, vol. 34, p. 63–65. doi: 10.1016/j.msard.2019.06.017
Main files (1)
Article (Published version)
ISSN of the journal2211-0348

Technical informations

Creation09/02/2019 4:23:00 PM
First validation09/02/2019 4:23:00 PM
Update time03/15/2023 5:58:52 PM
Status update03/15/2023 5:58:51 PM
Last indexation10/19/2023 11:04:21 AM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack